Brief: Immix Biopharma Announces 100% Overall Response Rate (N=10) 23.7 Months Best Response Duration (Ongoing) For Car-T Nxc-201 In Relapsed/Refractory Al Amyloidosis Patients At Ash 2023
11/12/2023 15:24
Dec 11 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA ANNOUNCES 100% OVERALL RESPONSE RATE
(N=10);
23.7 MONTHS BEST RESPONSE DURATION (ONGOING) FOR CAR-T NXC-201
IN RELAPSED/REFRACTORY AL AMYLOIDOSIS PATIENTS AT ASH 2023
* IMMIX BIOPHARMA INC - BEST RESPONDER DURATION OF RESPONSE
WAS
23.7 MONTHS WITH RESPONSE ONGOING AS OF DECEMBER 10, 2023
Source text for Eikon: ID:nGNX77fysC
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary